BMY
Price
$49.25
Change
+$0.20 (+0.41%)
Updated
Nov 26 closing price
Capitalization
100.26B
70 days until earnings call
Intraday BUY SELL Signals
RHHBY
Price
$48.47
Change
-$0.16 (-0.33%)
Updated
Nov 26 closing price
Capitalization
309.91B
63 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BMY vs RHHBY

Header iconBMY vs RHHBY Comparison
Open Charts BMY vs RHHBYBanner chart's image
Bristol-Myers Squibb
Price$49.25
Change+$0.20 (+0.41%)
Volume$11.37M
Capitalization100.26B
Roche Holding
Price$48.47
Change-$0.16 (-0.33%)
Volume$1.55M
Capitalization309.91B
BMY vs RHHBY Comparison Chart in %
BMY
Daily Signal:
Gain/Loss:
RHHBY
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
BMY vs. RHHBY commentary
Nov 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMY is a StrongBuy and RHHBY is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 27, 2025
Stock price -- (BMY: $49.25 vs. RHHBY: $48.47)
Brand notoriety: BMY: Notable vs. RHHBY: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BMY: 70% vs. RHHBY: 83%
Market capitalization -- BMY: $100.26B vs. RHHBY: $309.91B
BMY [@Pharmaceuticals: Major] is valued at $100.26B. RHHBY’s [@Pharmaceuticals: Major] market capitalization is $309.91B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $988.41B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $101.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BMY’s FA Score shows that 2 FA rating(s) are green whileRHHBY’s FA Score has 2 green FA rating(s).

  • BMY’s FA Score: 2 green, 3 red.
  • RHHBY’s FA Score: 2 green, 3 red.
According to our system of comparison, both BMY and RHHBY are a good buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BMY’s TA Score shows that 5 TA indicator(s) are bullish while RHHBY’s TA Score has 5 bullish TA indicator(s).

  • BMY’s TA Score: 5 bullish, 5 bearish.
  • RHHBY’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, RHHBY is a better buy in the short-term than BMY.

Price Growth

BMY (@Pharmaceuticals: Major) experienced а +7.56% price change this week, while RHHBY (@Pharmaceuticals: Major) price change was -0.14% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.85%. For the same industry, the average monthly price growth was +3.30%, and the average quarterly price growth was +17.38%.

Reported Earning Dates

BMY is expected to report earnings on Feb 05, 2026.

RHHBY is expected to report earnings on Jan 29, 2026.

Industries' Descriptions

@Pharmaceuticals: Major (+1.85% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RHHBY($310B) has a higher market cap than BMY($100B). RHHBY has higher P/E ratio than BMY: RHHBY (26.71) vs BMY (16.58). RHHBY YTD gains are higher at: 43.583 vs. BMY (-8.596). RHHBY has higher annual earnings (EBITDA): 18B vs. BMY (14.9B). BMY has more cash in the bank: 16.5B vs. RHHBY (12B). RHHBY has less debt than BMY: RHHBY (33B) vs BMY (51B). RHHBY has higher revenues than BMY: RHHBY (63.5B) vs BMY (48B).
BMYRHHBYBMY / RHHBY
Capitalization100B310B32%
EBITDA14.9B18B83%
Gain YTD-8.59643.583-20%
P/E Ratio16.5826.7162%
Revenue48B63.5B76%
Total Cash16.5B12B138%
Total Debt51B33B155%
FUNDAMENTALS RATINGS
BMY vs RHHBY: Fundamental Ratings
BMY
RHHBY
OUTLOOK RATING
1..100
2419
VALUATION
overvalued / fair valued / undervalued
1..100
5
Undervalued
14
Undervalued
PROFIT vs RISK RATING
1..100
9555
SMR RATING
1..100
2797
PRICE GROWTH RATING
1..100
4940
P/E GROWTH RATING
1..100
5115
SEASONALITY SCORE
1..100
8n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BMY's Valuation (5) in the Pharmaceuticals Major industry is in the same range as RHHBY (14) in the null industry. This means that BMY’s stock grew similarly to RHHBY’s over the last 12 months.

RHHBY's Profit vs Risk Rating (55) in the null industry is somewhat better than the same rating for BMY (95) in the Pharmaceuticals Major industry. This means that RHHBY’s stock grew somewhat faster than BMY’s over the last 12 months.

BMY's SMR Rating (27) in the Pharmaceuticals Major industry is significantly better than the same rating for RHHBY (97) in the null industry. This means that BMY’s stock grew significantly faster than RHHBY’s over the last 12 months.

RHHBY's Price Growth Rating (40) in the null industry is in the same range as BMY (49) in the Pharmaceuticals Major industry. This means that RHHBY’s stock grew similarly to BMY’s over the last 12 months.

RHHBY's P/E Growth Rating (15) in the null industry is somewhat better than the same rating for BMY (51) in the Pharmaceuticals Major industry. This means that RHHBY’s stock grew somewhat faster than BMY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BMYRHHBY
RSI
ODDS (%)
Bearish Trend 2 days ago
50%
Bearish Trend 2 days ago
46%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
52%
Bearish Trend 2 days ago
52%
Momentum
ODDS (%)
Bullish Trend 2 days ago
44%
Bullish Trend 2 days ago
49%
MACD
ODDS (%)
Bullish Trend 2 days ago
46%
Bullish Trend 2 days ago
63%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
51%
Bearish Trend 2 days ago
51%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
51%
Bullish Trend 2 days ago
50%
Advances
ODDS (%)
Bullish Trend 2 days ago
52%
Bullish Trend 17 days ago
52%
Declines
ODDS (%)
Bearish Trend 14 days ago
54%
Bearish Trend 8 days ago
46%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
63%
Bearish Trend 2 days ago
37%
Aroon
ODDS (%)
Bearish Trend 2 days ago
52%
Bearish Trend 2 days ago
46%
View a ticker or compare two or three
Interact to see
Advertisement
BMY
Daily Signal:
Gain/Loss:
RHHBY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EALT35.170.16
+0.46%
Innovator U.S. Equity 5 To 15 Buf ETF-Qt
SCHP26.980.06
+0.22%
Schwab US TIPS ETF™
PFN7.44N/A
N/A
PIMCO Income Strategy Fund II
IIGD24.90N/A
-0.01%
Invesco Investment Grade Defensive ETF
DABS51.10-0.07
-0.13%
Doubleline Asset-Backed Securities ETF

RHHBY and

Correlation & Price change

A.I.dvisor indicates that over the last year, RHHBY has been loosely correlated with RHHVF. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if RHHBY jumps, then RHHVF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RHHBY
1D Price
Change %
RHHBY100%
-0.33%
RHHVF - RHHBY
65%
Loosely correlated
-0.90%
NVS - RHHBY
37%
Loosely correlated
+0.14%
JNJ - RHHBY
37%
Loosely correlated
+0.43%
RHHBF - RHHBY
32%
Poorly correlated
-1.91%
BMY - RHHBY
28%
Poorly correlated
+0.41%
More